Integrated Treatment for Opioid Use Disorder and PTSD
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorMedical University of South Carolina
About this trial
This study will test a therapy intervention, HOPE, for individuals with opioid use disorder and posttraumatic stress disorder. Interested individuals will need to be taking medications for opioid use disorder (e.g., suboxone, naltrexone, methadone). Interested participants will complete a 10-12 week therapy, and be asked to complete surveys.
Eligibility criteria
Qualifiers
Any gender; any race or ethnicity; aged 18-70 years old.
English-speaking
Meet DSM-5 diagnostic criteria for OUD.
Meet DSM-5 diagnostic criteria for PTSD and have some memory of their index traumatic event.
Disqualifiers
Participants presenting with psychiatric contraindications (e.g., unmanaged psychosis or mania, or bipolar) will be excluded and referred clinically.
Participants considered an immediate suicide risk, with current suicidal ideation and a plan of intent, or displaying other high-risk behaviors (i.e., MOUD refusal, risky fentanyl use, etc.), as determined by the PI and study team. These individuals will complete a safety plan and be referred for treatment.
Participants meeting DSM-5 criteria for a concurrent, non-opioid, substance use disorder and who report that the other substance is their primary substance of use. These participants will be referred clinically for treatment.
Participants enrolled in ongoing evidence-based psychotherapy for substance use disorders or PTSD outside of medications for OUD and standard psychotherapy groups in treatment programs.
Trial design
Treatments tested in this trial
- HOPE Therapy
Treatment groups
76 Participants
are divided into 2 treatment groupsSponsors and collaborators
Medical University of South Carolina
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator
National Institutes of Health (NIH)
Collaborator
Source ClinicalTrials.gov